SENNOS

Journal of Drug Delivery and Biotherapeutics (JDDB)

Journal homepage: https://sennosbiotech.com/JDDB/1

Review Article

Advances in the Delivery of Biopharmaceuticals: Monoclonal Antibodies, Peptides, and Pulmonary mRNA and Gene Therapy

Manju Zade*

[1]Navjeevan Multispeciality Hospital, Hingoli, MH India 441513

ARTICLEINFO

ABSTRACT

The rapid evolution of biopharmaceuticals, including monoclonal antibodies, peptides, and nucleic acid-based therapies, has revolutionized modern medicine. However, their clinical translation is often hindered by challenges in delivery, such as poor bioavailability, instability, and inadequate targeting. This review provides a comprehensive analysis of cutting-edge delivery strategies for biopharmaceuticals, with a focus on monoclonal antibodies and peptides, as well as emerging approaches for pulmonary mRNA and gene therapy. We explore innovative delivery systems, including nanoparticle-based carriers, lipid-based formulations, and advanced pulmonary delivery devices, which enhance therapeutic efficacy and minimize off-target effects. Furthermore, we discuss the potential of mRNA and gene therapies for treating respiratory diseases, emphasizing the role of the lungs as a prime target for non-invasive delivery. By addressing current limitations and future prospects, this review highlights the transformative potential of advanced delivery systems in unlocking the full therapeutic potential of biopharmaceuticals.

Keywords: Biopharmaceutical Delivery, Monoclonal Antibodies, Pulmonary mRNA Therapy, Nanoparticle Drug Carriers, Gene Therapy Innovations

Corresponding Author:

Manju Zade*

Navjeevan Multispeciality Hospital, Hingoli, MH India 441513

E-mail addresses: zademanju21@gmail.com

Received date: 10-Jan-2025 Revised date: 25-Jan-2025, Accepted date: 15-Feb-2025

1. Introduction

Biopharmaceuticals, including monoclonal antibodies, peptides, and nucleic acid-based therapies, have emerged as transformative tools in modern medicine, offering targeted and personalized treatment options for a wide range of diseases, including cancer, autoimmune disorders, and genetic conditions [1]. Monoclonal antibodies (mAbs), for instance, have revolutionized oncology and immunology due to their high specificity and ability to modulate immune responses [2]. Similarly, peptides have gained attention for their versatility in drug design, enabling the development of therapies with enhanced selectivity and reduced toxicity [3]. More recently, the success of mRNA vaccines during the COVID-19 pandemic has underscored the potential of nucleic acid-based therapies, particularly in the context of pulmonary delivery for respiratory diseases [4].

Despite their therapeutic promise, the clinical application of biopharmaceuticals is often limited by challenges in delivery. Monoclonal antibodies and peptides face issues such as poor oral bioavailability, enzymatic degradation, and immunogenicity, necessitating innovative delivery strategies to enhance their stability and targeting [5]. Similarly, mRNA and gene therapies, while groundbreaking, require efficient delivery systems to overcome barriers such as cellular uptake, endosomal escape, and immune recognition [6]. The lungs, with their large surface area and non-invasive accessibility, have emerged as a promising target for the delivery of mRNA and gene therapies, particularly for treating respiratory diseases like cystic fibrosis and chronic obstructive pulmonary disease (COPD) [7].

This review aims to provide a comprehensive overview of the latest advancements in the delivery of biopharmaceuticals, with a focus on monoclonal antibodies, peptides, and pulmonary mRNA/gene therapies. We will explore cutting-edge delivery systems, including nanoparticle-based carriers, lipid formulations, and advanced pulmonary delivery devices, while addressing the challenges and opportunities in this rapidly evolving field. By integrating recent research and clinical insights, this review seeks to highlight the transformative potential of advanced delivery systems in overcoming current limitations and unlocking the full therapeutic potential of biopharmaceuticals.

2. Monoclonal Antibodies (mAbs)

2.1 Overview

Monoclonal antibodies (mAbs) are engineered proteins designed to bind specifically to target antigens, making them powerful tools for treating diseases such as cancer, autoimmune disorders, and infectious diseases [8]. Their high specificity and ability to modulate immune responses have led to the approval of over 100 therapeutic mAbs, with many more in clinical development [9]. Despite their success, the delivery of mAbs remains a significant challenge due to their large molecular size, susceptibility to degradation, and limited tissue penetration [10].

2.2 Delivery Challenges

The delivery of mAbs is hindered by several factors. Poor oral bioavailability is a major issue, as the gastrointestinal tract degrades proteins, making oral delivery ineffective [11]. Immunogenicity is another concern, as mAbs can trigger immune responses, leading to reduced efficacy and adverse effects [12]. Additionally, their large size restricts diffusion into

dense tissues, such as solid tumors, limiting their therapeutic potential [13]. Furthermore, mAbs often have a short half-life in the bloodstream, necessitating frequent dosing to maintain therapeutic levels [14].

2.3 Delivery Strategies

To overcome these challenges, several innovative delivery strategies have been developed. Subcutaneous and intramuscular administration routes offer patient convenience and improved pharmacokinetics compared to traditional intravenous delivery [15]. Nanoparticle-based carriers, such as liposomes and polymeric nanoparticles, have shown promise in enhancing the stability of mAbs, prolonging their circulation time, and enabling targeted delivery to specific tissues or cells [16]. Additionally, advancements in protein engineering, such as the development of Fc-fusion proteins and antibody-drug conjugates, have improved the pharmacokinetics and therapeutic efficacy of mAbs [17]. These strategies collectively address the limitations of mAb delivery, paving the way for more effective and patient-friendly therapies (Table 1).

Table 1: Delivery Strategies for Monoclonal Antibodies

Strategy	Description	Advantages	Challenges
Subcutaneous Injection	Administration under the skin	Patient convenience, reduced healthcare visits	Limited volume, potential for local reactions
Nanoparticle Carriers	Encapsulation in liposomes or polymeric nanoparticles	Enhanced stability, targeted delivery, prolonged circulation	Complex manufacturing, potential toxicity
Fc-Fusion Proteins	Fusion of mAbs with Fc regions to extend half-life	Improved pharmacokinetics, reduced dosing frequency	Limited applicability to specific mAbs
Antibody-Drug Conjugates	mAbs linked to cytotoxic drugs for targeted delivery	Enhanced therapeutic efficacy, reduced off-target effects	Risk of linker instability, potential toxicity

3. Peptides

3.1 Overview

Peptides have emerged as versatile therapeutic agents due to their high specificity, low toxicity, and ability to modulate complex biological pathways [18]. They are composed of short chains of amino acids and can be designed to mimic natural proteins or interact with specific molecular targets, making them valuable for treating conditions such as diabetes, cancer, and cardiovascular diseases [19]. Despite their potential, the delivery of peptides faces significant challenges, including poor stability, rapid clearance, and limited bioavailability [20].

3.2 Delivery Challenges

The therapeutic application of peptides is often limited by their inherent physicochemical properties. Peptides are susceptible to enzymatic degradation in the gastrointestinal tract and bloodstream, which restricts their oral bioavailability [21]. Additionally, their small size and hydrophilic nature result in rapid renal clearance, reducing their half-life in the body [22]. Furthermore, peptides often struggle to cross biological barriers, such as the blood-brain barrier or cell membranes, limiting their ability to reach intracellular targets [23]. These challenges necessitate the development of advanced delivery systems to enhance the stability, bioavailability, and targeting of peptide-based therapeutics.

3.3 Delivery Strategies

Several strategies have been developed to address the delivery challenges associated with peptides. Chemical modifications, such as the incorporation of non-natural amino acids or cyclization, have been shown to improve peptide stability and resistance to enzymatic degradation [24]. Nanocarriers, including liposomes, polymeric nanoparticles, and micelles, have been widely explored to protect peptides from degradation, prolong their circulation time, and enable targeted delivery to specific tissues or cells [25]. Additionally, conjugation with cell-penetrating peptides (CPPs) or fatty acids has been used to enhance the cellular uptake and bioavailability of therapeutic peptides [26]. These approaches collectively aim to overcome the limitations of peptide delivery, enabling their broader application in clinical settings.

4. Pulmonary mRNA and Gene Therapy

4.1 Overview

The lungs represent a highly accessible and promising target for the delivery of mRNA and gene therapies, particularly for the treatment of respiratory diseases such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis [27]. The large surface area, extensive vascularization, and relatively non-invasive access via inhalation make the lungs an ideal site for localized and systemic delivery of nucleic acid-based therapies [28]. mRNA and gene therapies offer the potential to address the root causes of genetic and acquired diseases by enabling the production of therapeutic proteins or correcting defective genes directly within target cells [29]. However, the delivery of these therapies to the lungs remains a significant challenge due to barriers such as mucus clearance, immune recognition, and inefficient cellular uptake [30].

4.2 Delivery Challenges

The delivery of mRNA and gene therapies to the lungs is complicated by several physiological and biological barriers. The respiratory tract is lined with a mucus layer that can trap and clear inhaled

particles, reducing the efficiency of delivery [31]. Additionally, the immune system can recognize exogenous nucleic acids, triggering inflammatory responses that may compromise therapeutic efficacy [32]. Furthermore, achieving efficient cellular uptake and endosomal escape of mRNA or gene-editing tools remains a critical hurdle, as these molecules must reach the cytoplasm or nucleus to exert their therapeutic effects [33]. These challenges highlight the need for innovative delivery systems that can overcome these barriers and enable precise and effective targeting of lung tissues.

4.3 Delivery Strategies

Recent advancements in delivery technologies have significantly improved the prospects of pulmonary mRNA and gene therapy. Lipid-based nanoparticles (LNPs) have emerged as a leading platform for mRNA delivery, offering protection from degradation and facilitating cellular uptake [34]. Inhalable dry powder formulations and nebulized solutions have been developed to enhance the deposition of nucleic acid therapeutics in the lungs while minimizing systemic exposure [35]. Additionally, viral vectors, such as adeno-associated viruses (AAVs), have been engineered for efficient gene delivery to lung cells, although concerns about immunogenicity and insertional mutagenesis remain [36]. Non-viral vectors, including polymeric nanoparticles and peptide-based carriers, are also being explored as safer alternatives for gene delivery [37]. These strategies collectively aim to address the challenges of pulmonary delivery, paving the way for transformative treatments for respiratory diseases.

Conclusion

The delivery of biopharmaceuticals, including monoclonal antibodies, peptides, and nucleic acid-based therapies, represents a cornerstone of modern medicine, offering unprecedented opportunities for the treatment of complex diseases. However, the clinical translation of these therapies is often hindered by challenges related to stability, bioavailability, and targeted delivery. This review has highlighted the remarkable progress made in addressing these challenges through innovative delivery strategies. For monoclonal antibodies, advancements in subcutaneous administration, nanoparticle-based carriers, and protein engineering have significantly improved their therapeutic potential [15, 16, 17]. Similarly, peptides have benefited from chemical modifications, nanocarriers, and conjugation strategies that enhance their stability and cellular uptake [24, 25, 26]. In the realm of pulmonary mRNA and gene therapy, lipid-based nanoparticles, inhalable formulations, and advanced viral and non-viral vectors have shown great promise in overcoming the unique barriers of the respiratory tract [34, 35, 36, 37].

Despite these advancements, several challenges remain, including the need for improved targeting, reduced immunogenicity, and scalable manufacturing processes. Future research should focus on the development of next-generation delivery systems that integrate smart materials, biomimetic designs, and personalized approaches to further enhance the efficacy and safety of biopharmaceuticals. By addressing these challenges, the field can unlock the full potential of biopharmaceuticals, paving the way for transformative therapies that improve patient outcomes and redefine the treatment of diseases.

Conflict of Interest

The authors declare no conflict of interest.

Funding

No Funding

References

1. Walsh G. Biopharmaceutical benchmarks 2022. Nat Biotechnol. 2022;40(12):1722-1760.
2. Kaplon H, Reichert JM. Antibodies to watch in 2023. MAbs. 2023;15(1):2153410.
3. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122-128.
4. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-279.
5. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655-672.
6. Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017;35(3):222-229.
7. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1(4):338-344.
8. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7(1):9-14.
9. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1-30.
10. Kontermann RE. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs. 2009;23(2):93-109.
11. Hamman JH, Enslin GM, Kotzé AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs. 2005;19(3):165-177.
12. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325-338.
13. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653-664.
14. Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493-507.
15. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548-558.
16. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4(3):e10143 .
17. Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.
18. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700-2707.
19. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future

directions. Drug Discov Today. 2015;20(1):122-128.

20. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010;15(1-2):40-56.
21. Hamman JH, Enslin GM, Kotzé AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs. 2005;19(3):165-177.
22. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des. 2013;81(1):136-147.
23. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol. 2009;157(2):195-206.
24. Henninot A, Collins JC, Nuss JM. The current state of peptide drug discovery: back to the future? J Med Chem. 2018;61(4):1382-1414.
25. Malavolta L, Cabral H. Peptide-based nanoparticles for systemic therapeutic delivery. Adv Ther. 2021;4(1):2000123.
26. Copolovici DM, Langel K, Eriste E, Langel Ü. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano. 2014;8(3):1972-1994.
27. Mastorakos P, da Silva AL, Chisholm J, Song E, Choi WK, Boyle MP, et al. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci U S A. 2015;112(28):8720-8725.
28. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67-74.
29. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759-780.
30. Griesenbach U, Alton EWFW. Progress in gene and cell therapy for cystic fibrosis lung disease. Curr Pharm Des. 2012;18(5):642-662.
31. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28-51.
32. Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017;9(1):60.
33. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541-555.
34. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094.
35. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1-2):1-19.
36. Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20(5):e3015 .
37. Lostalé-Seijo I, Montenegro J. Synthetic materials at the forefront of gene delivery. Nat Rev Chem. 2018;2(10):258-277.